What strategies prevent and manage opioid-induced constipation in palliative care?

Study for ELNEC 4: Symptom Management in Palliative Care Test with flashcards and multiple choice questions. Hints and explanations included! Get ready for your exam!

Multiple Choice

What strategies prevent and manage opioid-induced constipation in palliative care?

The main idea is proactive, multimodal prevention and management of opioid-induced constipation as part of ongoing opioid therapy. Opioids slow gut motility by activating mu receptors in the bowel, so constipation often develops early and can worsen comfort and function if not addressed. Start a bowel regimen from the moment opioid therapy begins. Use a combination approach: a stimulant laxative to stimulate peristalsis and an osmotic laxative to soften stool and draw water into it, with the plan adjusted over time based on response. Ensure adequate fluids if possible and establish a regular bowel routine with ongoing monitoring of stool frequency and consistency. If constipation occurs or intensifies, tailor the regimen—increase laxative type or dose, add stools softeners if appropriate, and reassess fluids and activity. If constipation remains refractory despite optimized laxatives, consider a peripherally acting mu-opioid receptor antagonist such as methylnaltrexone, or other agents like naloxegol or naldemedine, which can relieve the constipation without compromising analgesia. Important: do not discontinue opioids to treat constipation; continue pain control while addressing the bowel symptoms. Nonpharmacologic steps (hydration, mobility as feasible) can complement the regimen, but the primary strategy is prophylactic, regular, multi-agent bowel management with escalation as needed. This approach reduces the risk and severity of constipation and improves patient comfort in palliative care.

The main idea is proactive, multimodal prevention and management of opioid-induced constipation as part of ongoing opioid therapy. Opioids slow gut motility by activating mu receptors in the bowel, so constipation often develops early and can worsen comfort and function if not addressed.

Start a bowel regimen from the moment opioid therapy begins. Use a combination approach: a stimulant laxative to stimulate peristalsis and an osmotic laxative to soften stool and draw water into it, with the plan adjusted over time based on response. Ensure adequate fluids if possible and establish a regular bowel routine with ongoing monitoring of stool frequency and consistency. If constipation occurs or intensifies, tailor the regimen—increase laxative type or dose, add stools softeners if appropriate, and reassess fluids and activity.

If constipation remains refractory despite optimized laxatives, consider a peripherally acting mu-opioid receptor antagonist such as methylnaltrexone, or other agents like naloxegol or naldemedine, which can relieve the constipation without compromising analgesia.

Important: do not discontinue opioids to treat constipation; continue pain control while addressing the bowel symptoms. Nonpharmacologic steps (hydration, mobility as feasible) can complement the regimen, but the primary strategy is prophylactic, regular, multi-agent bowel management with escalation as needed. This approach reduces the risk and severity of constipation and improves patient comfort in palliative care.

More practice questions